Every 10-Q that InMed Pharmaceuticals Inc. (INM) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow INM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INM filings page.
InMed Pharmaceuticals Inc. reported lower commercial revenue and continuing losses for the three and six months ended December 31, 2025, while flagging substantial doubt about its ability to continue as a going concern. BayMedica’s rare‑cannabinoid business faces potential prohibition under new U.S. legislation, which could force inventory write‑offs or exit. The company also highlighted an arbitration over a technology license where the counterparty is seeking significant royalty payments, noting that an unfavorable outcome could materially harm its financial condition and BayMedica’s operations.
InMed Pharmaceuticals (INM) reported Q1 FY2026 results with Commercial segment sales of $1,120,121 versus $1,264,638 a year ago, reflecting lower pricing amid competition. Gross profit was $403,159 and the company recorded a net loss of $1,726,899 (basic and diluted EPS $(0.44)), compared with a net loss of $1,677,868 last year. Research and development expenses in the Pharma segment fell 17% to $575,458, while Commercial general and administrative costs rose 59% to $292,957.
Liquidity and balance sheet: Cash, cash equivalents and short‑term investments were $9,373,936 as of September 30, 2025, with cash and cash equivalents at $9,331,077. Total assets were $13,361,085, liabilities $1,770,462, and shareholders’ equity $11,590,623. Management states these resources are expected to fund operations into the fourth quarter of calendar 2026, yet concludes there is “substantial doubt” about continuing as a going concern. The quarter included the exercise of 602,000 pre-funded warrants, with an additional 200,000 exercised after quarter-end. Shares outstanding were 2,804,186 as of October 31, 2025.